Fingerprint
Dive into the research topics of 'Rejoinder to “A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III”'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Rejoinder to “A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III”
Andrew G. Chapple, Peter F. Thall
Research output: Contribution to journal › Article › peer-review